NASDAQ$ZIMV

ZimVie Inc · Q4 2024 earnings

Q4 2024 earnings · · After market close · Investor relations

Briefing

ZimVie reported its fourth quarter and full year 2024 financial results, showing a decrease in net sales but an improvement in net loss and adjusted EBITDA.

ZimVie reported fourth quarter 2024 net sales of $111.5 million, a 1.4% decrease from the previous year. Despite this, the company significantly improved its net loss, reducing it to $(9.7) million from $(22.2) million in Q4 2023, and saw an increase in adjusted EBITDA to $18.4 million.

  • Fourth quarter 2024 net sales were $111.5 million, a decrease of 1.4% on a reported basis compared to Q4 2023.
  • Net loss for Q4 2024 improved significantly to $(9.7) million from $(22.2) million in Q4 2023.
  • Adjusted EBITDA for Q4 2024 increased to $18.4 million, up from $13.9 million in Q4 2023.
  • Diluted EPS for Q4 2024 was $(0.35), while adjusted diluted EPS was $0.27.

Headline financials

Total Revenue

$112M

Previous: $113M-1.4%
EPS (adj)

$0.27

Previous: $0.10+170.0%
Adjusted EBITDA

$18.4M

Previous: $13.9M+32.4%
Adjusted EBITDA Margin

16.5%

Previous: 12.3%+34.1%
Net Loss Margin

-8.7%

Previous: -19.6%+55.6%
Capital Expenditures

-$2.69M

Previous: -$2.81M+4.2%
Net Income

-$9.67M

Previous: -$22.2M+56.5%
Operating Income

-$6.33M

Previous: -$15.3M+58.6%
Gross Profit

$66.8M

Previous: $64.4M+3.8%
R&D Expense

$6.62M

Previous: $6.89M-4.0%

Revenue & EPS history

ZimVie · Revenue · Quarterly

$112M

Q4 2024-1.4%vs Q4 2023
Beat estimate in 9 of 14 quarters(64%)
ActualEstimate

Forward guidance

For the full year 2025, ZimVie projects net sales between $445 million and $460 million, representing a flat to 3% growth in constant currency. Adjusted EBITDA is expected to be between $65 million and $70 million, an 8% to 17% increase, and adjusted EPS is projected to be between $0.80 and $0.95, a 31% to 55% increase.

Tailwinds

  • Projected constant currency net sales growth of Flat to 3%.
  • Anticipated Adjusted EBITDA growth of 8% to 17%.
  • Expected Adjusted EPS growth of 31% to 55%.
  • Continued optimism about long-term drivers of the dental implant market.
  • Well-positioned to take advantage of growth in dental implant and digital solutions market.

Headwinds

  • Net sales projected to be between (1%) to 2% on a reported basis, indicating potential slight decline.
  • No specific negative factors were highlighted in the forward guidance section.
  • The guidance does not provide a detailed breakdown of potential challenges.
  • Reliance on continued success of training and education programs.
  • Market conditions could impact actual results.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 6 quarterly earnings reports · overlaid with Q4 2024

Historical avgQ4 2024

-1.7%

Avg return

Earnings day

-3.4%

Avg return

5 days after

-5.3%

Avg return

30 days after

44%

8 / 18 earnings

Positive

+24.0%

Q1 2023

Best reaction

-49.0%

Q4 2022

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q3 2025
Q2 2025-0.4%-0.1%+0.1%
Q1 2025-4.4%-4.8%+2.2%
Q4 2024-1.7%+3.1%-11.9%
Q3 2024+0.6%+5.5%+6.2%
Q2 2024-18.2%-19.0%-17.9%
Q1 2024+5.7%+4.8%+0.8%
Q4 2023-14.4%-13.4%-16.9%
Q3 2023+5.4%
Q2 2023-6.0%
Q1 2023+24.0%
Q4 2022-49.0%
Q3 2021+20.0%
Q3 2022+20.0%
Q2 2021-8.2%
Q2 2022-8.2%
Q1 2021-6.5%
Q4 2021+5.1%
Q4 2020+5.1%

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro